Top Searches
Advertisement

Dividend Surprises and Rights Bonanza: Tanla, Max India, and Annvrridhhi Ventures Drive Market Buzz


Updated: April 29, 2025 09:23

Image Source: Good Returns
Investors are closely watching Tanla Platforms, Max India, and Annvrridhhi Ventures this week, as these companies roll out key corporate actions including dividends and rights issues, setting the stage for heightened market activity.
 
Key Highlights:
 
Tanla Platforms Declares Interim Dividend:
Tanla Platforms, India’s leading CPaaS provider, declared a second interim dividend of ₹6 per share for FY25, despite a 9.9% year-on-year drop in Q4 net profit to ₹117.3 crore. Revenue for the quarter rose a modest 1.9% to ₹1,024.4 crore, with EBITDA margin holding steady at 16%. The record date for dividend eligibility is set for April 30, 2025, and payment will be made by May 30. Tanla’s focus on shareholder returns stands out amid challenging market conditions, even as the company navigates muted topline growth and margin pressures.
 
Max India Rights Issue Opens Soon:
Max India has announced a rights issue of 82.82 lakh equity shares, totaling up to ₹124.23 crore. The rights issue ratio is 19:100, meaning shareholders will get 19 rights entitlements for every 100 shares held as of the record date, April 29, 2025. The subscription window runs from May 7 to May 22, 2025, giving existing investors a chance to increase their stake at a fixed price of ₹150 per share.
 
Annvrridhhi Ventures Rights Issue:
Annvrridhhi Ventures will issue 3.24 crore shares at ₹15 each (including a ₹5 premium per share), aggregating to ₹48.6 crore. The record date for eligibility is April 11, 2025. The company is currently under Graded Surveillance Measure (GSM) on the BSE.
 
These corporate actions are expected to drive trading volumes and investor interest, keeping these stocks firmly in focus this week.
 
Sources: Tanla Platforms, Angel One, Moneycontrol, Max India, Business Standard, CNBC-TV18

Advertisement

STORIES YOU MAY LIKE

Advertisement

Advertisement